Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1800046-95-0
2. Gs-syk
3. Lanraplenib [inn]
4. Lanraplenib [usan]
5. Lanraplenib (gs-9876)
6. A6u64ou57e
7. 6-(6-aminopyrazin-2-yl)-n-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine
8. Gs-9876
9. 6-(6-amino-2-pyrazinyl)-n-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]-imidazo[1,2-a] 10. 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine
11. 6-(6-amino-2-pyrazinyl)-n-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)imidazo(1,2-a)pyrazin-8-amine
12. Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-n-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-
13. 6-(6-aminopyrazin-2-yl)-n-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine
14. Gs-syk?
15. Lanraplenib (usan/inn)
16. Lanraplenib [usan:inn]
17. Unii-a6u64ou57e
18. Lanraplenib [who-dd]
19. Gtpl9764
20. Chembl3986824
21. Schembl16820581
22. Example 2 [us9290505]
23. Bdbm212271
24. Bcp30292
25. Ex-a3747
26. Gs9876
27. S9715
28. Who 10601
29. Db14770
30. Gs-9876gs-9876
31. Ex.-2, Us9290505
32. Us9290505, Ex.-2
33. Compound 39 [pmid: 32292557]
34. Ac-36571
35. Hy-109091
36. Cs-0039383
37. C92666
38. D11596
39. Gs-9876; Gs9876; Gs 9876
40. 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazol[1,2-a]pyrazin-8-amine
| Molecular Weight | 443.5 g/mol |
|---|---|
| Molecular Formula | C23H25N9O |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 443.21820645 g/mol |
| Monoisotopic Mass | 443.21820645 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 635 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Lanraplenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lanraplenib, including repackagers and relabelers. The FDA regulates Lanraplenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lanraplenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lanraplenib supplier is an individual or a company that provides Lanraplenib active pharmaceutical ingredient (API) or Lanraplenib finished formulations upon request. The Lanraplenib suppliers may include Lanraplenib API manufacturers, exporters, distributors and traders.
Lanraplenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lanraplenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lanraplenib GMP manufacturer or Lanraplenib GMP API supplier for your needs.
A Lanraplenib CoA (Certificate of Analysis) is a formal document that attests to Lanraplenib's compliance with Lanraplenib specifications and serves as a tool for batch-level quality control.
Lanraplenib CoA mostly includes findings from lab analyses of a specific batch. For each Lanraplenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lanraplenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lanraplenib EP), Lanraplenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lanraplenib USP).
LOOKING FOR A SUPPLIER?
